Venous stent experience in Arnsberg Michael K. W. Lichtenberg MD, FESC

Size: px

Start display at page:

Download "Venous stent experience in Arnsberg Michael K. W. Lichtenberg MD, FESC"

Adela Barber
6 years ago
Views:

1 Venous stent experience in Arnsberg Michael K. W. Lichtenberg MD, FESC

2 IMPORTANT INFORMATION: These materials are intended to describe common clinical considerations and procedural steps for the on-label use of referenced technologies as well as current standards of care for certain conditions. Of course, patients and their medical circumstances vary, so the clinical considerations and procedural steps described may not be appropriate for every patient or case. As always, decisions surrounding patient care depend on the physician s professional judgment in light of all available information for the case at hand. Boston Scientific Corporation ( BSC ) does not promote or encourage the use of its devices outside their approved labeling. The presenter s experience with BSC products may not be interpreted or relied upon to support clinical claims about BSC devices or product comparison claims regarding BSC and competitive devices. The experiences of other users may vary. Results from case studies are not necessarily predictive of results in other cases. Results in other cases may vary. PI AA Jan2018

Conflict of Interest - Disclosure Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

3 Conflict of Interest - Disclosure Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial Relationship Company 1. Honoraria for lectures: CR Bard, Veniti, AB Medica, Volcano, Optimed GmbH, Straub Medical, Terumo, Biotronik, Veryan 2. Honoraria for advisory board activities: Veniti, Optimed GmbH, Straub Medical, Biotronik, Veryan, Boston Scientific 3. Participation in clinical trials: Biotronik, CR Bard, Veryan, Straub Medical, Veniti, TVA Medical, Boston Scientific, LimFlow 4. Research funding: Biotronik, Boston Scientific, Veryan, Veniti, AB Medica

4 Venous Center Arnsberg 4 study coordinators and nurses Associated clinical research organization (CliPS-Clinical Project Services) 2 associated medical writers 2 associated biostatistician > 250 endovascular venous outflow obstruction treatments / year

5 Venous Center Arnsberg Unilateral and/or bilateral swelling of lower extremity (no CHF, liver dysfunction or renal causes) Abdominal mass? Ultrasound analysis for reflux, DVT and CVOO Compression stocking Persistent pain and swelling C3 INTRAVASCULAR ULTRASOUND PLUS VENOGRAPHY DVT NIVL Reflux deep veins Reflux sup. veins Thrombectomy ± IVUS guided Stent implantation IVUS guided Stent implantation Compression stocking Clinical follow up 1, 6, 12 months Ablation, etc.

6 Our way of venous stenting philosophy there is not a perfect venous stent for the whole system..

7 Different venous stents for different locations High radial force Radial force plus flexibility flexibility, kink resistance, low fracture rate

8 Wrong stent design for May-Thurner PI AA Jan2018

9 Venous Stent Attributes Self-expandable Crush resistant across length of stent Sufficient chronic outward force Sufficient wall coverage Flexibility sufficient to resist kink at physiological angles Durability allowing repeated shortening, twisting, and bending at the groin Minimal foreshortening on deployment and balloon dilation Predictable, consistent deployment Strength Flexibility Lumen quality

10 What do we know about venous outflow? No hemodynamic measure of obstruction With constant perimeter, improvement in shape (roundness) increases area Therefore, is shape a better predictor of improved flow?

11 How to define shape? Shape defined by Aspect Ratio Aspect Ratio = Maximum Diameter to Minimum Diameter Aspect Ratio Perfect Circle Diameter = 14 Max Diameter = 14 Min Diameter = 7 Max Diameter = 14 Min Diameter = Smaller Aspect Ratio = Better Lumen Quality

Ratio 1:2, or 2) Significant stent compression was inversely correlated with stent patency (p < 0.

12 48 patients with iliac compression and acute DVT followed for average of 20 months Follow-up was performed with CT venography Stent compression considered significant if lumen compression was greater than 50% (Aspect Ratio 1:2, or 2) Significant stent compression was inversely correlated with stent patency (p < 0.001) Cho H, Kim JK. Stent Compression in IVCS Associated with Acute Ilio-Femoral DVT. Korean J Radiol. 2015;16(4):

VIRTUS Study Feasibility Cohort Data Analysis of IVUS Measurements Pre-Stent Post-Stent 12 months Aspect Ratio 2.

13 For a Given Perimeter (stented vessel) Fluid Dynamics Suggest: Round lumens provide larger areas and better flow Aspect Ratio is a better predictor of lumen quality and clinical improvement than Area? VIRTUS Study Feasibility Cohort Data Analysis of IVUS Measurements Pre-Stent Post-Stent 12 months Aspect Ratio Area (sq mm) Bench test/preclinical results may not necessarily be indicative of clinical performance.

Pharmacomechanical Catheter-Directed Thrombolysis for

14 One word on ATTRACT Reality In 59 % of cases no dedicated venous stent was used Vedantham S, et al. Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. N Engl J Med Dec 7;377(23):

15 Arnsberg Venous Registry > 300 patients included since 2013 Objective Assess safety & effectiveness in achieving patency of target venous lesion through 36 months post venous stent placement in patients with non thrombotic iliac vein lesions and post thrombotic iliac vein lesions. Effectiveness Primary 12-M // Clinical 12 -M Principal Investigators Dr. Michael Lichtenberg Dr. Rick de Graaf Study Design Ongoing prospective, single arm, single center non-randomized registry FU 1 (4 weeks), FU 2 (6 months), FU 3 (12 months), FU 4 (24 months), FU 5 (36 months) Patient Population Subjects with clinically significant chronic non-malignant obstruction of the iliofemoral venous segment Study is sponsored by German Venous Center Arnsberg

16 Arnsberg Venous Registry VENITI VICI VENOUS STENT System Objective Assess safety & effectiveness in achieving patency of target venous lesion through 36 months post stent placement (VENITI VICI Stent) Effectiveness Primary 12-M // Clinical 12 -M Principle Investigators Dr. Michael Lichtenberg Dr. Rick de Graaf Study Design Ongoing prospective, single arm, single center non-randomized registry FU 1 (4 weeks), FU 2 (6 months), FU 3 (12 months), FU 4 (24 months), FU 5 (36 months) Patient Population Subjects with clinically significant chronic non-malignant obstruction of the iliofemoral venous segment

17 Clinical assessment PI AA Jan2018

18 Demographic / Clinical data 90 patients Demographic/comorbidity No. (%) Age 57.4±16.4 Male 43 (48%) Female 47 (52%) Post-thrombotic Syndrome 49 (54%) Non-thrombotic 41 (46%) History of venous 81 (90%) thromboembolic disease Pulmonary embolism 22 (24%) Deep vein thrombosis 43 (48%) Coronary Artery Disease 6 (7%) Myocardial Infarction 1 (1%) Congestive Heart Failure 7 (8%) High Blood Pressure 48 (55%) Renal Disease 6 (7%) Stroke 3 (3%) Cancer 13 (14%) Diabetes 13 (14%) Smoker (current or previous) a 15 (17%) CEAP score, prior to stenting 1 0 (0%) 2 1 (1%) 3 56 (62%) 4 20 (22%) 5 8 (9%) 6 4 (4%) Signs and symptoms, prior to stenting b Pain (inc. venous claudication) 89 (99%) Varicose veins 83 (92%) Edema 89 (99%) Pigment Changes 41 (46%) Ulcers 10 (11%) Use of compression stockings 88 (98%)

19 Lesion location All Patients Left Right No. (%) No. (%) No. (%) Unilateral 83 (92%) 67 (74%) 16 (18%) Bilateral 7 (8%) CIV 40 (44%) 35 (39%) 5 (6%) EIV 13 (14%) 4 (4%) 9 (10%) CFV 4 (4%) 2 (2%) 2 (2%) CIV + EIV 22 (24%) 20 (22%) 2 (2%) EIV + CFV 6 (7%) 3 (3%) 3 (3%) CIV + EIV + CFV 12 (13%) 10 (11%) 2 (2%)

20 Primary 12 months 12 months

21 Patency rates non-thrombotic vs. post-thrombotic 12 months 12 months

22 Clinical efficacy: rvcss analysis Baseline 1 month P value 6 months P value 12 months P value N=90 N=56 N=29 N=13 All Patients 8 (4, 27) 4 (1, 15) < (0, 12) < (0, 15).008 PTS [N=49 a ] 8 (5, 20) 4 (1, 15) < (0, 9) < (2, 15).19 NIVL [N=41 b ] 8 (4, 27) 5 (2, 15) < (2, 12) < (0, 7).007

23 5 4, Mean CEAP score (±SD) , ,5 2 1,5 1 0,5 N=90 N=82 N=50 N=21 0 Baseline FU1 FU2 FU3

VIRTUS Study Design Objective Safety Assess safety & effectiveness in achieving patency of target venous lesion through 12-M post stent placement MAEs @ 30 days Post-thrombotic Effectiveness Primary

Joseph s Orange Prospective, multicenter, single arm nonrandomized, conducted at 22 sites worldwide 200 subjects with clinically significant chronic nonmalignant obstruction of the iliofemoral venous

24 VIRTUS Study Design Objective Safety Assess safety & effectiveness in achieving patency of target venous lesion through 12-M post stent placement 30 days Post-thrombotic Effectiveness Primary 12-M Principal Investigators Study Design Patient Population Dr. William Marston, UNC Chapel Hill Dr. Mahmood Razavi, St. Joseph s Orange Prospective, multicenter, single arm nonrandomized, conducted at 22 sites worldwide 200 subjects with clinically significant chronic nonmalignant obstruction of the iliofemoral venous segment Feasibility Cohort 1 st 30 patients Image Courtesy of Mr. Stephen Black Non-thrombotic Etiologies: Post Thrombotic (75%); Non Thrombotic (25%) Core Labs Venography: Syntactx IVUS: St. Lukes DUS: VasCore/MGH X-Ray: Syntactx Image Courtesy of Dr. Mahmood Razavi

25 Target Lesion Location Lesion 1 Location Patients N = 30 Left N = 25 (83%) CIV lesions 11/30 (37%) EIV lesions 4/30 (13%) CIV & EIV lesions 6/30 (20%) Lesions that extended into CFV 2 9/30 (30%) Right N = 5 (17%) Average Target Lesion Length 12.8 (3-24.7) cm 1. Some patients have more than 1 lesion or lesion extends in multiple vein segments 2. No lesions were isolated to the CFV alone Razavi M, et al. J Vasc Surg Venous Lymphat Disord Dec 28. pii: S X(17)

26 12-month Patency Data Secondary 100% Assisted-primary 96% Primary 93% Razavi M, et al. J Vasc Surg Venous Lymphat Disord Dec 28. pii: S X(17)

27 Patient Outcome Measures 63% of patients had 50% VCSS score reduction 81% of patients with pain reduction at 12 months 78% of patients considered QOL improved Baseline N=30 6 months N=26* P value 12 months N=27 P value VCSS 1 10 (2-25) 5 (0-30) < (0-23) <.001 VAS 2 60 (6-98) 23 (0-84) (0-94).001 CIVIQ (24-97) 28 (20-91) (20-89) <.001 * At 6 months, 27 patients had VCSS scores. The 1 patient with 6-month VCSS data (and no VAS or CIVIQ- 20 data) at 6 months only had completed form responses for 3 of 10 VCSS domains (all 0 s). 1. VCSS venous clinical severity score 2. VAS visual analogue scale 3. CIVIQ-20 chronic venous insufficiency quality of life questionnaire Razavi M, et al. J Vasc Surg Venous Lymphat Disord Dec 28. pii: S X(17)

28 Conclusions Use dedicated venous stents! Choose wisely - based on lesion morphology Choose wisely based on stent technology Initial 6 and 12-Month efficacy data in the VIRTUS Trial and Arnsberg Venous Registry are promising Patients feel substantially better 85% of population showed symptomatic improvement after venous stenting (VCSS 2) at 12-Months Safety data raise no concerns 28

29 Venous stent experience in Arnsberg Michael K. W. Lichtenberg MD, FESC

Patency rates and clinical results of the Veniti VICI Stent for treatment of iliac vein lesion Data from the Arnsberg Venous Registry

Patency rates and clinical results of the Veniti VICI Stent for treatment of iliac vein lesion Data from the Arnsberg Venous Registry Michael K. W. Lichtenberg MD, FESC Conflict of Interest - Disclosure